Artificial intelligence in coronary plaque characterization and risk assessment: from images to impact
Attilio Lauretti , Marco Borgi , Francesco Versaci
Vessel Plus ›› 2025, Vol. 9 ›› Issue (1) : 16
Accurate characterization of coronary atherosclerotic plaque and individualized cardiovascular risk assessment remain active challenges in clinical and interventional cardiology. In recent times, Artificial Intelligence (AI) has emerged as a powerful new tool able to support clinicians in determining diagnoses and prognoses from coronary imaging. This commentary focuses on the current applications of AI in coronary plaque imaging, particularly on coronary computed tomography angiography (CCTA), intravascular ultrasound (IVUS), and optical coherence tomography (OCT), evaluating its role in identifying high-risk plaque features and predicting future adverse cardiovascular events. We discuss limitations of conventional assessment methods, illustrating how AI algorithms can improve reproducibility, reduce operator dependence, and examine current evidence from registries and clinical studies. Furthermore, some key challenges remain to be addressed, including data quality, model generalizability, clinical integration, and regulatory concerns. We argue that AI’s promise lies not in replacing clinical expertise, but in empowering coronary risk stratification and characterization. Ongoing validation and clinician-AI collaboration will be essential to ensure meaningful patient outcomes.
Artificial intelligence / coronary plaque / risk stratification
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
Veelen A, van der Sangen NMR, Henriques JPS, Claessen BEPM. Identification and treatment of the vulnerable coronary plaque.Rev Cardiovasc Med2022;23:39 |
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
Wikimedia Commons. CCTA CAD-RADS 4a.png. Available from: https://commons.wikimedia.org/wiki/File:CCTA_CAD-RADS_4a.png [Last accessed on 15 Sep 2025] |
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
Abbott. UltreonTM 1.0 software: experience the power of automation. Available from: https://www.cardiovascular.abbott/int/en/hcp/products/percutaneous-coronary-intervention/intravascular-imaging/ultreon-software/ultreon-1-0.html [Last accessed on 15 Sep 2025] |
| [37] |
Boston Scientific. AVVIGOTM+ Multi-Modality Guidance System. Available from: https://www.bostonscientific.com/en-US/products/ffr-ivus-systems/avvigo-guidance-system.html [Last accessed on 15 Sep 2025] |
| [38] |
|
| [39] |
|
| [40] |
HeartFlow. Heartflow introduces next generation interactive plaque analysis platform to assess patient risk in suspected coronary artery disease. Available from: https://www.heartflow.com/press-release/Heartflow-plaque-interactive/ [Last accessed on 15 Sep 2025] |
| [41] |
Cleerly. Not all plaque analysis software are the same: roviding multi-modality imaging decision support. Available from: https://cleerlyhealth.com/plaque-analysis [Last accessed on 15 Sep 2025] |
| [42] |
Siemens Healthineers. AI-Rad Companion: providing multi-modality imaging decision support. Available from: https://www.siemens-healthineers.com/en-us/digital-health-solutions/ai-rad-companion [Last accessed on 15 Sep 2025] |
| [43] |
|
| [44] |
NANOX. Nanox receives FDA clearance for HealthCCSng V2.0, upgraded version of advanced AI cardiac solution empowering physicians in assessment of coronary artery calcium. Available from: https://investors.nanox.vision/news-releases/news-release-details/nanox-receives-fda-clearance-healthccsng-v20-upgraded-version [Last accessed on 15 Sep 2025] |
| [45] |
|
/
| 〈 |
|
〉 |